Evaluation of macular structure and function by OCT and electrophysiology in patients with vitelliform macular dystrophy due to mutations in BEST1

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 9, 2010, Pages 4754-4765

  Schatz, Patrik ^a,b,c   Bitner, Hanna ^d   Sander, Birgit ^a   Holfort, Stig ^a   Andreasson, Sten ^b   Larsen, Michael ^a   Sharon, Dror ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c JOHN F KENNEDY INSTITUTE   (Denmark)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ASPARTIC ACID; CYTOSINE; GLUTAMIC ACID; BEST1 PROTEIN, HUMAN; CHLORIDE CHANNEL; EYE PROTEIN;

ADULT; AGED; ARTICLE; BEST1 GENE; CHOROID; CLINICAL ARTICLE; CONSANGUINITY; ELECTRORETINOGRAPHY; ETHNIC GROUP; EYE FUNDUS; FEMALE; FUNCTIONAL ASSESSMENT; GENE; GENE SEQUENCE; GENETIC ANALYSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LATENT PERIOD; MALE; MISSENSE MUTATION; OPTICAL COHERENCE TOMOGRAPHY; PHOTORECEPTOR INNER SEGMENT; PHOTORECEPTOR OUTER SEGMENT; PRIORITY JOURNAL; RETINA EDEMA; RETINA FOVEA; RETINA MACULA LUTEA; RETINA MACULA VITELLIFORM DEGENERATION; RETINA ROD; SENSORY SYSTEM ELECTROPHYSIOLOGY; STRUCTURE ANALYSIS; SWEDISH; AMINO ACID SEQUENCE; CHILD; ELECTROOCULOGRAPHY; FAMILY HEALTH; FLUORESCENCE; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PEDIGREE; RETINA MACULA DEGENERATION;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CHILD; CHLORIDE CHANNELS; ELECTROOCULOGRAPHY; EYE PROTEINS; FAMILY HEALTH; FEMALE; FLUORESCENCE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEDIGREE; TOMOGRAPHY, OPTICAL COHERENCE; YOUNG ADULT;

EID: 77955901553     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5152     Document Type: Article

References (36)

1. Eksandh L, Bakall B, Bauer B, Wadelius C, Andreasson S. Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene. Ophthalmic Genet. 2001;22:107-115.
2. Ponjavic V, Eksandh L, Andreasson S, et al. Clinical expression of Best's vitelliform macular dystrophy in Swedish families with mutations in the bestrophin gene. Ophthalmic Genet. 1999;20:251-257.
3. Sohn EH, Francis PJ, Duncan JL, et al. Phenotypic variability due to a novel Glu292Lys variation in exon 8 of the BEST1 gene causing best macular dystrophy. Arch Ophthalmol. 2009;127:913-920.
4. Burgess R, Millar ID, Leroy BP, et al. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet. 2008; 82:19-31.
5. Yardley J, Leroy BP, Hart-Holden N, et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci. 2004;45:3683-3689.
6. Davidson AE, Millar ID, Urquhart JE, Burgess-Mullan R, et al. Missense mutations in a retinal pigment epithelium protein, bestrophin- 1, cause retinitis pigmentosa. Am J Hum Genet. 2009;85: 581-592.
7. Schatz P, Ponjavic V, Andréasson S, Dahl N. Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet. 2006;27:51-56.
8. Guziewicz KE, Zangerl B, Lindauer SJ, et al. Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci. 2007;48:1959-1967.
9. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000;7:97:12758-12763.
10. Hartzell C, Qu Z, Putzier I, Artinian L, Chien LT, Cui Y. Looking chloride channels straight in the eye: bestrophins, lipofuscinosis, and retinal degeneration. Physiology. 2005;20:292-302.
11. Rosenthal R, Bakall B, Kinnick T, et al. Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. FASEB J. 2006; 20:178-180.
12. Xiao Q, Yu K, Cui YY, Hartzell HC. Dysregulation of human bestrophin-1 by ceramide-induced dephosphorylation. J Physiol. 2009;587:4379-4391.
13. Fishman GA, Baca W, Alexander KR, Derlacki DJ, Glenn AM, Viana M. Visual acuity in patients with best vitelliform macular dystrophy. Ophthalmology. 1993;100:1665-1670.
14. Mohler CW, Fine SL. Long-term evaluation of patients with Best's vitelliform dystrophy. Ophthalmology. 1981;88:688-692.
15. Schatz P, Ponjavic V, Andreasson S, McGee TL, Dryja TP, Abrahamson M. Clinical phenotype in a Swedish family with a mutation in the IMPDH1 gene. Ophthalmic Genet. 2005;26:119-124.
16. Andersen MK, Christoffersen NL, Sander B, et al. Oligocone trichromacy: clinical and molecular genetic investigations. Invest Ophthalmol Vis Sci. 2010;51:89-95.
17. Boon CJ, Theelen T, Hoefsloot EH, et al. Clinical and molecular genetic analysis of best vitelliform macular dystrophy. Retina. 2009;29:835-847.
18. White K, Marquardt A, Weber BH. VMD2 mutations in vitelliform macular dystrophy (Best disease) and other maculopathies. Hum Mutat. 2000;15:301-308.
19. Krämer F, White K, Pauleikhoff D, et al. Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet. 2000;8:286-292.
20. Qu Z, Cheng W, Cui Y, Cui Y, Zheng J. Human disease-causing mutations disrupt an N-C-terminal interaction and channel function of bestrophin 1. J Biol Chem. 2009;284:16473-16481.
21. Bakall B, Radu RA, Stanton JB, et al. Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res. 2007;85:34-43.
22. Marchant D, Yu K, Bigot K, et al. New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy. J Med Genet. 2007;44:e70.
23. Gränse L, Abrahamson M, Ponjavic V, Andréasson S. Electrophysiological findings in two young patients with Bothnia dystrophy and a mutation in the RLBP1 gene. Ophthalmic Genet. 2001;22:97-105.
24. Scholl HP, Schuster AM, Vonthein R, Zrenner E. Mapping of retinal function in Best macular dystrophy using multifocal electroretinography. Vision Res. 2002;42:1053-1061.
25. Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:948-954.
26. Han Y, Schneck ME, Bearse MA Jr, et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:4106-4112.
27. Eksandh L, Ekström U, Abrahamson M, Bauer B, Andréasson S. Different clinical expressions in two families with Stargardt's macular dystrophy (STGD1). Acta Ophthalmol Scand. 2001;79:524-530.
28. Pianta MJ, Aleman TS, Cideciyan AV, et al. In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res. 2003;76:203-211.
29. Mullins RF, Oh KT, Heffron E, Hageman GS, Stone EM. Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation. Arch Ophthalmol. 2005; 123:1588-1594.
30. Boon CJ, Klevering BJ, den Hollander AI, et al. Clinical and genetic heterogeneity in multifocal vitelliform dystrophy. Arch Ophthalmol. 2007;125:1100-1106.
31. Schatz P, Preising M, Lorenz B, et al. Lack of autofluorescence of the fundus in fundus albipunctatus associated with mutations in RDH5. Retina. In press.
32. Sieving PA, Chaudhry P, Kondo M, et al. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci U S A. 2001;98:1835-1840.
33. Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol. 1999;128:185-191.
34. Holm K, Larsson J, Lövestam-Adrian M. In diabetic retinopathy, foveal thickness of 300 micrometer seems to correlate with functionally significant loss of vision. Doc Ophthalmol. 2007;114:117-124.
35. Ergun E, Hermann B, Wirtitsch M, et al. Assessment of central visual function in Stargardt's disease/fundus flavimaculatus with ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci. 2005;46:310-316.
36. Querques G, Regenbogen M, Quijano C, et al. High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol. 2008;146:501-507.